HKEx Reforms Attract High-Profile Technology and Biotech Listings

Published date19 June 2019
Subject MatterChina,Shareholders,Publicly-Traded Companies,EU,Biotechnology,Threshold Requirements,HKEx,Listing Rules,Hong Kong Stock Exchange,Research and Development,United States,Dual Class Share Structures,Corporate Executives,Innovative Technology,Patent Registration,Food and Drug Administrations,Weighted Voting Rights (WVR)
AuthorChristopher Betts,Antony Dapiran,Paloma Wang
Law FirmSkadden, Arps, Slate, Meagher & Flom LLP

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT